A lower cost option for testing is Adalimumab Activity and 
Neutralizing Antibody, LAB8152.

Obtaining pre-authorization to estimate patient out-of-pocket 
liability is strongly recommended.  Once obtained draw sample at 
patient's next available visit.  Please use the reference link below 
for authorization.

Patient's insurance information must be submitted with the sample.

Advantages
•Anser™ IFX can detect low levels of ATI even in the presence 
 of high levels of circulating drug (60μg/mL of IFX in serum)
•Anser™ IFX can be performed at any time during therapy with
 IFX, with no trough level sampling limitation
•High assay sensitivity, specificity, and accuracy
•Use Anser™ IFX to help determine personalized solutions for
 managing loss of response to IFX

Please print, complete, and submit the Pre-Authorization Form and the Prometheus Test Requisition from Prometheus Lab.